EGF104900 trial
A Phase III, multicentre, randomised, open-label trial comparing lapatinib alone versus lapatinib with Herceptin in patients with HER2-positive MBC after progression on previous treatment with Herceptin.
EGF104900 trial
EU approval and labelling information
Herceptin is approved for the treatment of women with early and metastatic HER2-positive breast cancer and patients with HER2-positive metastatic gastric cancer.
- Disclaimer: Herceptin.net is a comprehensive resource for healthcare professionals outside the US. If you are a US resident please visit www.herceptin.com. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
- © 2010 F. Hoffmann-La Roche Ltd.